A 72-year-old male with end-stage heart failure is admitted to the ICU with cardiogenic shock and multi-organ failure. He is intubated, on mechanical ventilation, and receiving a dobutamine infusion. His family is distressed and unsure about his treatment preferences, noting that he completed some advance care documents years ago. As the critical care pharmacist advising the medical team, which framework should be prioritized in the upcoming family meeting to ensure treatment aligns with the patient’s values and preferences?

A 72-year-old male is admitted to the ICU after a severe anoxic brain injury following cardiac arrest. He is intubated, on assist-control ventilation, and receiving a norepinephrine infusion. The patient remains unresponsive. His wife presents an undated, handwritten document she calls his “living will,” which vaguely states a desire to “not be kept alive artificially if there is no hope of recovery.” However, one adult child insists the patient would want “everything done” based on recent conversations. The medical team seeks guidance on ethically and legally appropriate steps to manage care given unclear advance directives and family disagreement. As the critical care pharmacist, you are asked to advise the team on the MOST appropriate initial step to ensure legally and ethically sound decision-making, considering advance care planning principles and relevant legal frameworks.

A 75-year-old man with a large right intracerebral hemorrhage involving the basal ganglia and evidence of transtentorial herniation is intubated and mechanically ventilated in the ICU. His Glasgow Coma Scale is 5 (E1V1M3). Neurosurgical evaluation indicates minimal chance of meaningful neurological recovery. During a goals-of-care meeting, the patient’s adult children express hope for full recovery and ask the team to “do everything,” but they appear overwhelmed and unable to grasp the prognosis. The critical care pharmacist recognizes that the primary barrier to shared decision-making is the family’s poor understanding of the patient’s likely outcome and their unrealistic expectations. Which of the following interventions should the critical care pharmacist prioritize to address this barrier?

A 78-year-old woman with metastatic pancreatic cancer has been in the ICU for 12 days with refractory septic shock, on maximum vasopressors, mechanical ventilation, and continuous renal replacement therapy. Despite maximal support, her oncologic prognosis is terminal and the care team estimates virtually zero chance of recovery. Her family insists on “everything possible,” including CPR and further invasive measures that the team considers medically futile and likely to prolong suffering. In preparing for this goals-of-care discussion, which ethical principle should the critical care team emphasize?

A 68-year-old man is admitted to the ICU with septic shock secondary to community-acquired pneumonia. He has received aggressive fluid resuscitation (30 mL/kg crystalloid) and is on escalating vasopressor support (norepinephrine 0.2 mcg/kg/min plus vasopressin 0.04 U/min). Broad-spectrum antimicrobials (piperacillin–tazobactam and vancomycin) have been administered for 48 hours. He remains hypotensive (MAP 55 mmHg) with a lactate of 6 mmol/L, and has developed severe ARDS requiring lung-protective ventilation (6 mL/kg IBW) with PEEP of 16 cm H₂O. He is anuric despite a continuous furosemide infusion. His SOFA score is 15, indicating severe multi-organ failure with an estimated mortality risk >70%. As the critical care pharmacist, which of the following actions should you prioritize?

In the ICU, you are part of the multidisciplinary team managing Ms. Elena Rodriguez, a 72-year-old intubated patient with severe sepsis. Her family primarily speaks Spanish, expresses distrust of healthcare providers, and is culturally reluctant to discuss end-of-life planning. As the critical care pharmacist, which intervention best addresses social determinants of health to facilitate advance care planning?

A 68-year-old man with metastatic non–small cell lung cancer is admitted to the ICU with severe ARDS. He is on high-dose vasopressors for refractory shock, has rising lactate levels, acute kidney injury requiring CRRT, and thrombocytopenia. His APACHE II score is 32 and SOFA score is 15, indicating a very high risk of mortality. His code status is currently full code, and there is no documented advance directive. His wife and two adult children are at the bedside as surrogate decision-makers. The ICU team—including critical care nursing, the intensivist, and the clinical pharmacist—asks you to recommend the highest-priority action regarding goals of care. Which of the following should the clinical pharmacist prioritize?

A 78-year-old male with severe COPD, heart failure, and early Alzheimer’s dementia is intubated and receiving vasopressors for acute hypoxic respiratory failure. His living will, created 5 years ago, broadly requests “no heroic measures” but does not address mechanical ventilation or artificial nutrition. As the critical care pharmacist, which action should you prioritize to facilitate advance care planning with the healthcare team and family?

A 68-year-old man with end-stage liver disease (total bilirubin 12 mg/dL) and chronic kidney disease stage 5 (creatinine 6.5 mg/dL) is admitted to the ICU for management of refractory pain and agitation as he transitions to comfort care. He has received continuous infusions of morphine 5 mg/h and midazolam 2 mg/h for 48 hours and continues to exhibit prolonged sedation after each dose adjustment. Which of the following regimens is most appropriate to optimize symptom control while minimizing drug accumulation and prolonged sedation in this patient?

A 78-year-old man with end-stage heart failure and chronic kidney disease is admitted to the ICU on assist-control mechanical ventilation and norepinephrine infusion. The family has decided to transition to comfort-focused care prioritizing symptom relief and withdrawal of life-sustaining treatments. Despite scheduled acetaminophen, he is grimacing, restless, moaning, and has a Richmond Agitation-Sedation Scale (RASS) score of +2. His blood pressure is 90/55 mmHg, heart rate 105 bpm, respiratory rate 22 with ventilator set at 14 breaths per minute, and SpO₂ 94% on FiO₂ 0.6. Considering the patient’s goals and clinical status, which pharmacotherapy plan is MOST appropriate to prioritize comfort while minimizing adverse effects?